Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CG5503 immediate-release for osteoarthritis pain in patients awaiting primary joint replacement surgery
2006-004514-40Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tapentadol in osteoarthritis (OA) (3 arms), sponsored by Johnson & Johnson. Primary endpoints: Sum of Pain Intensity Difference over 5 days, Pain intensity and 3 more. Started Nov 2006; status: completed.
02
Drugs
tapentadol
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on 2006-004514-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004514-40.